FDA accepts Foamix application for rosacea topical FMX103

Foamix Pharmaceuticals (NASDAQ:FOMX) is up 1% premarket on average volume in response to its announcement that the FDA has accepted for review its marketing application for FMX103 (minocycline topical foam 1.5%) for the treatment of adults with moderate-to-severe papulopustular rosacea.

The agency’s action date is June 2, 2020.

https://seekingalpha.com/news/3506484-fda-accepts-foamix-application-rosacea-topical-fmx103-shares-1-percent